Research programme: anti-cancer therapeutics - MicroQuin Therapeutics
Latest Information Update: 03 Sep 2021
At a glance
- Originator MicroQuin
- Class Antineoplastics
- Mechanism of Action Bcl-X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Ovarian cancer
Most Recent Events
- 03 Sep 2021 Preclinical trials in Breast cancer in USA (unspecified route) (MicroQuin company pipeline, September 2021)
- 03 Sep 2021 Preclinical trials in Ovarian cancer in USA (unspecified route) (MicroQuin company pipeline, September 2021)